B+
Bull case
25%
Probability
Target price
$8.50
+138.8% vs current
CATX
Perspective TherapeuticsDNYSE American / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$4.25
+19.4% vs current
B-
Bear case
30%
Probability
Target price
$2.00
-43.8% vs current
AI sentiment snapshot
Latest data as of 2026-04-28
Recent news sentiment (30D)
-0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+77.1
Score
AI commentary
Primary-source context improved with the April 20, 2026 8-K and incorporated press-release update, but the name still screens as a cautious monitoring setup: recent news flow is sparse in the packet, analyst-reaction depth is unavailable, and the deterministic score bundle remains negative with modest evidence quality (0.54) and low catalyst density (0.25). With no usable social-context packet and no broad trusted-news confirmation, sentiment should be treated as fragile and highly event-driven rather than trend-confirmed.
RankAlpha Sentiment Codex - 2026-04-28
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventAdditional VMT-α-NET efficacy data expected later in 2026High impact
The April 20, 2026 company update said initial efficacy data from an additional 23 patients in Cohort 2 and the first eight patients in Cohort 3 are expected later in 2026, after interim data showed objective response in 43% of the first 23 Cohort 2 patients and continued tolerability; this is the clearest near-term information event for the stock [#PR-2026-04-20] [#8-K-2026-04-20].
2026-12-31event2026 regulatory-engagement package around VMT-α-NETHigh impact
Management said it remains on track to submit a robust clinical evidence package for medical-conference presentation and regulatory engagement in 2026 while running additional cohorts and subgroup work to optimize a potential registration-study design; any FDA feedback that clarifies path-to-registration would materially change sentiment for a low-coverage radiopharma name [#PR-2026-04-20] [#10-K-2026-03-16].
2027-09-30catalystRunway supports milestones into late 2027 but not the full development pathHigh impact
The 10-K says cash, cash equivalents, and short-term investments were $144.7 million at December 31, 2025 and, together with the February 2026 financing, should fund current clinical milestones and operational investments into late 2027, but the company also says substantial additional funds will be required within the next several years and could be needed sooner if the operating plan changes [#10-K-2026-03-16].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-28 • Updated nightlySource: Internal modelMethodology